Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Azoximer→

Azoximer Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
892497-01-7
Molecular formula
Not available
Molecular weight
Not available
Drug class
Synthetic polymer immunomodulator (polyoxidonium)mechanism-based class not established in major regulatory references
Mechanism of action
Proposed to modulate innate immune responses and phagocyte activity; a defined molecular target and mechanism of clinical benefit are not established in widely recognised FDA/EMA product labels.
Indications / reported uses
  • Used in selected countries for adjunctive prevention or treatment of recurrent infections under local product authorisations; there is no general FDA or EMA-authorised therapeutic indication to assign

Sources: PubMed — Azoximer bromide/polyoxidonium clinical evidence · NLM MeSH — Azoximer · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Azoximer Environmental Risk Assessment (ERA) (the Azoximer ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.